Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 325 versus OMNIPAQUE 240.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 325 versus OMNIPAQUE 240.
CONRAY 325 vs OMNIPAQUE 240
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays by blocking photons, allowing visualization of blood vessels and tissues.
Iodinated radiocontrast agent that attenuates X-rays due to high atomic number of iodine, enhancing vascular and tissue contrast during imaging procedures. It distributes in extracellular fluid and is excreted unchanged by glomerular filtration.
Intravenous: 1.0-2.0 mL/kg (325 mg I/mL) for contrast imaging; maximum total dose 250 mL.
Intravenous administration: 50-200 mL (12-48 g iodine) of OMNIPAQUE 240 (240 mg iodine/mL) as a single dose, adjusted for procedure and patient size.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. May be prolonged in renal impairment.
Terminal half-life approximately 1-2 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Primarily renal (glomerular filtration, no tubular reabsorption); >95% excreted unchanged in urine within 24 hours; <5% biliary/fecal
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent